Skip to main content

Advertisement

SpringerLink
Log in

Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Abraham S, Knapp DW, Cheng L et al (2006) Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12:353–360

    PubMed  CAS  Google Scholar 

  2. Ahmed S, Molife R, Shaw H et al (2006) Phase I dose-escalation study of ZK 304709, an oral multi-target tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle [Abstract 2076]. In: Proceeding of the American society of clinical oncology, vol 24

  3. Appels NMGM, Beijnen JH, Schellens JHM (2005) Development of Farnesyl transferase inhibitors: a review. Oncologist 10:565–578

    PubMed  Google Scholar 

  4. Bakkar AA, Wallerand H, Radvanyi F et al (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63:8108–8112

    PubMed  CAS  Google Scholar 

  5. Basso AD, Kirschmeier P, Bishop WR (2006) Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47:15–31

    PubMed  CAS  Google Scholar 

  6. Benson C, Kaye S, Workman P et al (2005) Clinical anticancer drug development: targeting the cyclin-dependent kinases. [Review] [54 refs]. Br J Cancer 92:7–12

    PubMed  CAS  Google Scholar 

  7. Bernard-Pierrot I, Brams A, Dunois-Larde C et al (2006) Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27:740–747

    PubMed  CAS  Google Scholar 

  8. Billerey C, Chopin D, Aubriot-Lorton MH et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955–1959

    PubMed  CAS  Google Scholar 

  9. Billerey C, Chopin D, Aubriot-Lorton MH et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955–1959

    PubMed  CAS  Google Scholar 

  10. Blaveri E, Brewer JL, Roydasgupta R et al (2005) Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 11:7012–7022

    PubMed  CAS  Google Scholar 

  11. Blaveri E, Simko JP, Korkola JE et al (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11:4044–4055

    PubMed  CAS  Google Scholar 

  12. Blehm KN, Spiess PE, Bondaruk JE et al (2006) Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12:4671–4677

    PubMed  CAS  Google Scholar 

  13. Bornman DM, Mathew S, Alsruhe J et al (2001) Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol 159:831–835

    PubMed  CAS  Google Scholar 

  14. Byrne RR, Shariat SF, Brown RICH et al (2001) E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 165:1473–1479

    PubMed  CAS  Google Scholar 

  15. Cairns P, Proctor AJ, Knowles MA (1991) Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 6:2305–2309

    PubMed  CAS  Google Scholar 

  16. Casetta G, Gontero P, Russo R et al (1997) p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. Eur Urol 32:229–236

    PubMed  CAS  Google Scholar 

  17. Chan S, Scheulen ME, Johnston S et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314–5322

    PubMed  CAS  Google Scholar 

  18. Chapman EJ, Harnden P, Chambers P et al (2005) Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 11:5740–5747

    PubMed  CAS  Google Scholar 

  19. Charlesworth PJ, Harris AL (2006) Mechanisms of disease: angiogenesis in urologic malignancies. Nat Clin Pract Urol 3:157–169

    PubMed  CAS  Google Scholar 

  20. Chatterjee SJ, Datar R, Youssefzadeh D et al (2004) Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22:1007–1013

    PubMed  CAS  Google Scholar 

  21. Chen J, Lee BH, Williams IR et al (2005) FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24:8259–8267

    PubMed  CAS  Google Scholar 

  22. Cheng HL, Trink B, Tzai TS et al (2002) Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 20:1544–1550

    PubMed  CAS  Google Scholar 

  23. Cheng JC, Weisenberger DJ, Gonzales FA et al (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24:1270–1278

    PubMed  CAS  Google Scholar 

  24. Chien Y, White MA (2003) RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep 4:800–806

    PubMed  CAS  Google Scholar 

  25. Connell PP, Weichselbaum RR, Connell PP et al (2003) Gene therapy: the challenges of translating laboratory research into clinical practice [comment]. J Clin Oncol 21:2230–2231

    PubMed  CAS  Google Scholar 

  26. Coogan CL, Estrada CR, Kapur S et al (2004) HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63:786–790

    PubMed  Google Scholar 

  27. Cooke PW, James ND, Ganesan R et al (2000) Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy [see comment]. BJU Int 85:829–835

    PubMed  CAS  Google Scholar 

  28. Copp HL, Chin JL, Conaway M et al (2006) Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma. Cancer 107:60–66

    PubMed  CAS  Google Scholar 

  29. Cordon-Cardo C, Wartinger D, Petrylak D et al (1992) Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 84:1251–1256

    PubMed  CAS  Google Scholar 

  30. Cortes J, Faderl S, Estey E et al (2005) Phase I study of BMS-214662, a Farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23:2805–2812

    PubMed  CAS  Google Scholar 

  31. Cote RJ, Esrig D, Groshen S et al (1997) p53 and treatment of bladder cancer. Nature 385:123–125

    PubMed  CAS  Google Scholar 

  32. Cote RJ, Laird PW, Datar RH (2005) Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer. J Clin Oncol 23:2879–2881

    PubMed  CAS  Google Scholar 

  33. Deininger MW, Druker BJ (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55:401–423

    PubMed  CAS  Google Scholar 

  34. Dimitroff CJ, Klohs W, Sharma A et al (1999) Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 17:121–135

    PubMed  CAS  Google Scholar 

  35. Dinney CP, McConkey DJ, Millikan RE et al (2004) Focus on bladder cancer. Cancer Cell 6:111–116

    PubMed  CAS  Google Scholar 

  36. Dyrskjot L, Kruhoffer M, Thykjaer T et al (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64:4040–4048

    PubMed  CAS  Google Scholar 

  37. Dyrskjot L, Zieger K, Kruhoffer M et al (2005) A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 11:4029–4036

    PubMed  CAS  Google Scholar 

  38. Erill N, Colomer A, Verdu M et al (2004) Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol 13:217–223

    PubMed  CAS  Google Scholar 

  39. Esrig D, Elmajian D, Groshen S et al (1994) Accumulation of Nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259–1264

    PubMed  CAS  Google Scholar 

  40. Feig LA (2003) Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 13:419–425

    PubMed  CAS  Google Scholar 

  41. Flamm M, Brodowicz T, Haitel A et al (2002) Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin. Anticancer Res 22:1295–1300

    PubMed  CAS  Google Scholar 

  42. Frank I, Cheville JC, Blute ML et al (2004) Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 101:1803–1808

    PubMed  Google Scholar 

  43. Frederick L, Wang XY, Eley G et al (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387

    PubMed  CAS  Google Scholar 

  44. Friedrich MG, Blind C, Milde-Langosch K et al (2001) Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur Urol 40:518–524

    PubMed  CAS  Google Scholar 

  45. Friedrich MG, Chandrasoma S, Siegmund KD et al (2005) Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 41(17):2769–2778

    PubMed  CAS  Google Scholar 

  46. Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 23:5294–5304

    PubMed  CAS  Google Scholar 

  47. Garcia dM X, Torregrosa A, Munoz J et al (2000) Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer 36:357–362

    Google Scholar 

  48. Gazzaniga P, Gandini O, Giuliani L et al (2001) Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. Clin Cancer Res 7:577–583

    PubMed  CAS  Google Scholar 

  49. Gildea JJ, Harding MA, Seraj MJ et al (2002) The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res 62:982–985

    PubMed  CAS  Google Scholar 

  50. Gildea JJ, Seraj MJ, Oxford G et al (2002) RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 62:6418–6423

    PubMed  CAS  Google Scholar 

  51. Gontero P, Banisadr S, Frea B et al (2004) Metastasis markers in bladder cancer: a review of the literature and clinical considerations. [Review] [215 refs]. Eur Urol 46(3):296–311, 46:296–311

    Google Scholar 

  52. Gontero P, Casetta G, Zitella A et al (2000) Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 38:287–296

    PubMed  CAS  Google Scholar 

  53. Grand EK, Chase AJ, Heath C et al (2004) Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 18:962–966

    PubMed  CAS  Google Scholar 

  54. Granville C, Memmott RM, Gills JJ et al (2006) Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/akt/mammalian target of rapamycin pathway. Clin Cancer Res 12:679–689

    PubMed  CAS  Google Scholar 

  55. Grossman HB, Liebert M, Antelo M et al (1998) p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4:829–834

    PubMed  CAS  Google Scholar 

  56. Habuchi T, Marberger M, Droller MJ et al (2005) Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology 66:64–74

    PubMed  Google Scholar 

  57. Hamad NM, Elconin JH, Karnoub AE et al (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16:2045–2057

    PubMed  CAS  Google Scholar 

  58. Hernandez S, Lopez-Knowles E, Lloreta J et al (2005) FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 11:5444–5450

    PubMed  CAS  Google Scholar 

  59. Hitchings AW, Kumar M, Jordan S et al (2004) Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br J Cancer 91:552–557

    PubMed  CAS  Google Scholar 

  60. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    PubMed  CAS  Google Scholar 

  61. Hussain M, Petrylak DP, Dunn R et al (2005) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced her2-positive urothelial carcinoma: results of a multi-center phase II NCI trial [Abstract 4507]. In: Proceeding of the American Society of clinical oncology, vol 24

  62. Inoue K, Kamada M, Slaton JW et al (2002) The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 8:1863–1870

    PubMed  CAS  Google Scholar 

  63. International Bladder Cancer Nomogram Consortium (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol:JCO

  64. Jankevicius F, Goebell P, Kushima M et al (2002) p21 and p53 immunostaining and survival following systemic chemotherapy for urothelial cancer. Urol Int 69:174–180

    PubMed  CAS  Google Scholar 

  65. Jebar AH, Hurst CD, Tomlinson DC et al (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24:5218–5225

    PubMed  CAS  Google Scholar 

  66. Jonsson G, Paulie S, Grandien A et al (2003) High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res 23:1213–1218

    PubMed  Google Scholar 

  67. Kakehi Y, Ozdemir E, Habuchi T et al (1998) Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res 89:214–220

    PubMed  CAS  Google Scholar 

  68. Kamai T, Takagi K, Asami H et al (2001) Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 84:1242–1251

    PubMed  CAS  Google Scholar 

  69. Kelly WK, Richon VM, O’Connor O et al (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578–3588

    PubMed  CAS  Google Scholar 

  70. Knowles MA (2001) What we could do now: molecular pathology of bladder cancer [Review] [81 refs]. Mol Pathol 54:215–221

    PubMed  CAS  Google Scholar 

  71. Knowles MA, Habuchi T, Kennedy W et al (2003) Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 63:7652–7656

    PubMed  CAS  Google Scholar 

  72. Knowles MA (2006) Molecular subtypes of bladder cancer: jekyll and hyde or chalk and cheese? Carcinogenesis 27:361–373

    PubMed  CAS  Google Scholar 

  73. Koed K, Wiuf C, Christensen LL et al (2005) High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 65:34–45

    PubMed  CAS  Google Scholar 

  74. Kohno M, Pouyssegur J, Kohno M et al (2006) Targeting the ERK signaling pathway in cancer therapy [Review] [73 refs]. Ann Med 38:200–211

    PubMed  CAS  Google Scholar 

  75. Korkolopoulou P, Christodoulou P, Konstantinidou AE et al (2000) Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Human Pathol 31(6):751–760

    CAS  Google Scholar 

  76. Kruger S, Mahnken A, Kausch I et al (2005) P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 47:463–467

    PubMed  Google Scholar 

  77. Kruger S, Weitsch G, Buttner H et al (2002) Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21:981–987

    PubMed  Google Scholar 

  78. Kurahashi T, Hara I, Oka N et al (2005) Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res 11:3773–3777

    PubMed  CAS  Google Scholar 

  79. Lacombe L, Dalbagni G, Zhang ZF et al (1996) Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette–Guerin therapy: correlation to clinical outcome. J Clin Oncol 14:2646–2652

    PubMed  CAS  Google Scholar 

  80. Lee CC, Yamamoto S, Morimura K et al (1997) Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 79:780–789

    PubMed  CAS  Google Scholar 

  81. Lee SH, Lopes de Menezes D, Vora J et al (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11:3633–3641

    PubMed  CAS  Google Scholar 

  82. Li Y, Mangasarian K, Mansukhani A et al (1997) Activation of FGF receptors by mutations in the transmembrane domain. Oncogene 14:1397–1406

    PubMed  CAS  Google Scholar 

  83. Lianes P, Charytonowicz E, Cordon-Cardo C et al (1998) Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. Clin Cancer Res 4(5):1267–1271

    PubMed  CAS  Google Scholar 

  84. Liang G, Gonzales FA, Jones PA et al (2002) Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 62:961–966

    Article  PubMed  CAS  Google Scholar 

  85. Lim KH, Baines AT, Fiordalisi JJ et al (2005) Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 7:533–545

    PubMed  CAS  Google Scholar 

  86. Lindgren D, Liedberg F, Andersson A et al (2006) Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene

  87. Lipponen PK (1993) Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53(3):365–370

    PubMed  CAS  Google Scholar 

  88. Lipponen P, Eskelinen M (1994) Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69:1120–1125

    PubMed  CAS  Google Scholar 

  89. Liu J, Wu X, Mitchell B et al (2005) A small-molecule agonist of the wnt signaling pathway. Angew Chem Int Ed 44:1987–1990

    CAS  Google Scholar 

  90. Liukkonen T, Lipponen P, Raitanen M et al (2000) Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res 28:285–292

    PubMed  CAS  Google Scholar 

  91. Liukkonen T, Rajala P, Raitanen M et al (1999) Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 36(5):393–400

    PubMed  CAS  Google Scholar 

  92. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al (2004) Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 45:606–612

    PubMed  CAS  Google Scholar 

  93. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al (2004) Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 122:444–452

    PubMed  Google Scholar 

  94. Lorenzo Romero JG, Salinas Sanchez AS, Gimenez Bachs JM et al (2004) p53 Gene mutations in superficial bladder cancer. Urol Int 73:212–218

    PubMed  CAS  Google Scholar 

  95. Lorenzo-Romero JG, Salinas-Sanchez AS, Gimenez-Bachs JM et al (2003) Prognostic implications of p53 gene mutations in bladder tumors. J Urol 169:492–499

    PubMed  CAS  Google Scholar 

  96. Lotan Y, Gupta A, Shariat SF et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23:6533–6539

    PubMed  Google Scholar 

  97. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    PubMed  CAS  Google Scholar 

  98. Lyons JF, Wilhelm S, Hibner B et al (2001) Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8:219–225

    PubMed  CAS  Google Scholar 

  99. Malats N, Kogevinas M, Amoros A, Lloreta J, Ferrer D, Serrano S, Tora M, Jaramillo R, Tardon A, Serra C, Carrato A, Real FX. Prognostic value of p53 in bladder cancer. Results of a multicentric study in spain. In: Proceedings of American Association for cancer research 200647. Ref type: generic

  100. Malats N, Bustos A, Nascimento CM et al (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6:678–686

    PubMed  CAS  Google Scholar 

  101. Maruyama R, Toyooka S, Toyooka KO et al (2001) Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61(24):8659–8663

    PubMed  CAS  Google Scholar 

  102. Masaki T (2004) Historical review: endothelin. Trends Pharmacol Sci 25:219–224

    PubMed  CAS  Google Scholar 

  103. Masters JR, Vani UD, Grigor KM et al (2003) Can p53 staining be used to identify patients with aggressive superficial bladder cancer? J Pathol 200:74–81

    PubMed  Google Scholar 

  104. Matsumoto H, Wada T, Fukunaga K et al (2004) Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol 34:124–130

    PubMed  Google Scholar 

  105. McKeown SR, Ward C, Robson T (2004) Gene-directed enzyme prodrug therapy: a current assessment. Curr Opin Mol Ther 6:421–435

    PubMed  CAS  Google Scholar 

  106. McNeish IA, Bell SJ, Lemoine NR (2004) Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther 11:497–503

    PubMed  CAS  Google Scholar 

  107. Mellon K, Wright C, Kelly P et al (1995) Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 153:919–925

    PubMed  CAS  Google Scholar 

  108. Messing EM (1990) Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 50:2530–2537

    PubMed  CAS  Google Scholar 

  109. Mhawech-Fauceglia P, Cheney RT, Fischer G et al (2006) FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 32:231–237

    PubMed  CAS  Google Scholar 

  110. Mhawech-Fauceglia P, Cheney RT, Schwaller J (2006) Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 106:1205–1216

    PubMed  CAS  Google Scholar 

  111. Mhawech-Fauceglia P, Fischer G, Beck A et al (2006) Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol

  112. Migaldi M, Sgambato A, Garagnani L et al (2000) Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 6:3131–3138

    PubMed  CAS  Google Scholar 

  113. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    PubMed  CAS  Google Scholar 

  114. Misra RN, Xiao HY, Kim KS et al (2004) N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47:1719–1728

    PubMed  CAS  Google Scholar 

  115. Mita M, Rowinsky E, Godston M et al (2004) Phase I, pharmacokinetic and pharmacodynamic study of an mTOR Inhibitor administered IV daily x 5 every other week in patients with refractory or advanced malignancies [Abstract 3076]. In: Proceeding of the American Society of clinical oncology, vol 46

  116. Mitra AP, Datar RH, Cote RJ (2005) Molecular staging of bladder cancer. BJU Int 96:7–12

    PubMed  CAS  Google Scholar 

  117. Monnerat C, Henriksson R, Le Chevalier T et al (2004) Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 15:316–323

    PubMed  CAS  Google Scholar 

  118. Monneret C (2005) Histone deacetylase inhibitors. Eur J Med Chem 40:1–13

    PubMed  CAS  Google Scholar 

  119. Monsonego-Ornan E, Adar R, Feferman T et al (2000) The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 20:516–522

    PubMed  CAS  Google Scholar 

  120. Naski MC, Wang Q, Xu J et al (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13:233–237

    PubMed  CAS  Google Scholar 

  121. O’Kane HF, Watson CJ, Johnston SR et al (2006) Targeting death receptors in bladder, prostate and renal cancer. J Urol 175:432–438

    PubMed  CAS  Google Scholar 

  122. Ong F, Moonen LM, Gallee MP et al (2001) Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 61:169–175

    PubMed  CAS  Google Scholar 

  123. Osman I, Kang M, Lee A et al (2004) Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int J Cancer 111:934–939

    PubMed  CAS  Google Scholar 

  124. Oxford G, Owens CR, Titus BJ et al (2005) RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res 65(16):7111–7120

    PubMed  CAS  Google Scholar 

  125. Oxford G, Theodorescu D (2003) The role of Ras superfamily proteins in bladder cancer progression. J Urol 170:1987–1993

    PubMed  CAS  Google Scholar 

  126. Pagliaro LC, Keyhani A, Williams D et al (2003) Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 21:2247–2253

    PubMed  CAS  Google Scholar 

  127. Pan J, Yeung SCJ (2005) Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 65:9109–9112

    PubMed  CAS  Google Scholar 

  128. Paterson JL, Li Z, Wen XY et al (2004) Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 124:595–603

    PubMed  CAS  Google Scholar 

  129. Pegram MD, Konecny G, Slamon DJ (2000) The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103:57–75

    PubMed  CAS  Google Scholar 

  130. Peyromaure M, Weibing S, Sebe P et al (2002) Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette–Guerin therapy. Urology 59:409–413

    PubMed  Google Scholar 

  131. Pfister C, Moore L, Allard P et al (1999) Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 5:4079–4084

    PubMed  CAS  Google Scholar 

  132. Philips G, Sanford S, Halabi D et al (2006) Phase II study of cisplatin, gemcitabine, and gefitinib for advanced urothelial carcinoma: analysis of the second cohort of CALGB 90102 [Abstract 4578]. In: Proceeding of the American Society of clinical oncology, vol 24

  133. Placer J, Espinet B, Salido M et al (2005) Correlation between histologic findings and cytogenetic abnormalities in bladder carcinoma: a FISH study. Urology 65:913–918

    PubMed  Google Scholar 

  134. Pollack A, Wu CS, Czerniak B et al (1997) Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 3:1823–1829

    PubMed  CAS  Google Scholar 

  135. Powis G, Ihle N, Kirkpatrick DL (2006) Practicalities of drugging the phosphatidylinositol-3-kinase/akt cell survival signaling pathway. Clin Cancer Res 12:2964–2966

    PubMed  CAS  Google Scholar 

  136. Pukac L, Kanakaraj P, Humphreys R et al (2005) HGS–ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92:1430–1441

    PubMed  CAS  Google Scholar 

  137. Quintero A, Alvarez-Kindelan J, Luque RJ et al (2006) Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 59:83–88

    PubMed  CAS  Google Scholar 

  138. Rajjayabun PH, Keegan PE, Lunec J et al (2005) erbB receptor expression patterns in human bladder cancer. Urology 66:196–200

    PubMed  CAS  Google Scholar 

  139. Rangarajan A, Hong SJ, Gifford A et al (2004) Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6:171–183

    PubMed  CAS  Google Scholar 

  140. Rauchenberger R, Borges E, Thomassen-Wolf E et al (2003) Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem 278:38194–38205

    PubMed  CAS  Google Scholar 

  141. Ravery V, Grignon D, Angulo J et al (1997) Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 25:9–17

    PubMed  CAS  Google Scholar 

  142. Retz M, Lehmann J, Szysnik C et al (2004) Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR. Eur Urol 45:314–319

    PubMed  CAS  Google Scholar 

  143. Ribeiro-Filho LA, Franks J, Sasaki M et al (2002) CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog 34:187–198

    PubMed  CAS  Google Scholar 

  144. Richon VM, Sandhoff TW, Rifkind RA et al (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014–10019

    PubMed  CAS  Google Scholar 

  145. Rinehart J, Adjei AA, Lorusso PM et al (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer [see comment]. J Clin Oncol 22:4456–4462

    PubMed  CAS  Google Scholar 

  146. Rodel C, Grabenbauer GG, Rodel F et al (2000) Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 46:1213–1221

    PubMed  CAS  Google Scholar 

  147. Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J et al (2002) p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 41:182–188

    PubMed  Google Scholar 

  148. Rosenberg JE, von der MH, Seigne JD et al (2005) A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 103:2035–2041

    PubMed  CAS  Google Scholar 

  149. Rotterud R, Nesland JM, Berner A et al (2005) Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 95:1344–1350

    PubMed  CAS  Google Scholar 

  150. Saint F, Frere Belda MA, Quintela R et al (2004) Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guerin (BCG). Eur Urol 45:475–482

    PubMed  Google Scholar 

  151. Sanborn RE, Blanke CD (2005) Gastrointestinal stromal tumors and the evolution of targeted therapy. Clin Adv Hematol Oncol 3:647–657

    PubMed  Google Scholar 

  152. Sanchez-Carbayo M, Socci ND, Lozano J et al (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24:778–789

    PubMed  CAS  Google Scholar 

  153. Sanchez-Carbayo M, Socci ND, Lozano J et al (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24:778–789

    PubMed  CAS  Google Scholar 

  154. Sarkis AS, Bajorin DF, Reuter VE et al (1995) Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13:1384–1390

    PubMed  CAS  Google Scholar 

  155. Sarkis AS, Dalbagni G, Cordon-Cardo C et al (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85(1):53–59

    PubMed  CAS  Google Scholar 

  156. Schlessinger J (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306:1506–1507

    PubMed  CAS  Google Scholar 

  157. Schmitz-Drager BJ, Goebell PJ, Ebert T et al (2000) p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 38:691–699

    PubMed  CAS  Google Scholar 

  158. Schultz IJ, Wester K, Straatman H et al (2006) Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int J Cancer 119:1915–1919

    PubMed  CAS  Google Scholar 

  159. Schulz WA (2006) Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119:1513–1518

    PubMed  CAS  Google Scholar 

  160. Sebti SM (2005) Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 7:297–300

    PubMed  CAS  Google Scholar 

  161. Sengelov L, Horn T, Steven K (1997) p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J Cancer Res Clin Oncol 123:565–570

    PubMed  CAS  Google Scholar 

  162. Sengupta S, Harris CC (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6:44–55

    PubMed  CAS  Google Scholar 

  163. Serth J, Kuczyk MA, Bokemeyer C et al (1995) p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71:201–205

    PubMed  CAS  Google Scholar 

  164. Sgambato A, Migaldi M, Faraglia B et al (2002) Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 97:671–678

    PubMed  CAS  Google Scholar 

  165. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1783

    PubMed  CAS  Google Scholar 

  166. Shariat SF, Tokunaga H, Zhou J et al (2004) p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer [see comment] J Clin Oncol 22:1014–1024

    PubMed  CAS  Google Scholar 

  167. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424–430

    PubMed  CAS  Google Scholar 

  168. Sheikh MS, Huang Y (2004) Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets 4:97–104

    PubMed  CAS  Google Scholar 

  169. Sherr CJ (2004) Principles of tumor suppression. Cell 116:235–246

    PubMed  CAS  Google Scholar 

  170. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    PubMed  CAS  Google Scholar 

  171. Smith SC, Oxford G, Wu Z et al (2006) The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 66:1917–1922

    PubMed  CAS  Google Scholar 

  172. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M et al (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54(3):784–788

    PubMed  CAS  Google Scholar 

  173. Strumberg D (2005) Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 41:773–784

    CAS  Google Scholar 

  174. Suwa Y, Takano Y, Iki M et al (1998) Cyclin D1 protein overexpression is related to tumor differentiation, but not to tumor progression or proliferative activity, in transitional cell carcinoma of the bladder. J Urol 160:897–900

    PubMed  CAS  Google Scholar 

  175. Sylvester RJ, van der Meijden APM, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477

    PubMed  Google Scholar 

  176. Tabernero J, Rojo F, Burris H et al (2005) A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors [Abstract 3007]. In: Proceeding of the American Society of clinical oncology, vol 23

  177. Takagi Y, Takashi M, Koshikawa T et al (2000) Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol 7:366–372

    PubMed  CAS  Google Scholar 

  178. Takata R, Katagiri T, Kanehira M et al (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11:2625–2636

    PubMed  CAS  Google Scholar 

  179. Takata R, Katagiri T, Kanehira M et al (2006) Validation study on the prediction of response to M-VAC neoadjuvant chemotherapy on the basis of expression profiles of 14 predictive genes [Abstract 1292]. In: Proceedings of American Association for Cancer Research, vol 47

  180. Tchevkina E, Agapova L, Dyakova N et al (2005) The small G-protein RalA stimulates metastasis of transformed cells. Oncogene 24:329–335

    PubMed  CAS  Google Scholar 

  181. Theodore C, Geoffrois L, Vermorken JB et al (2005) Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor and gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 41:1150–1157

    PubMed  CAS  Google Scholar 

  182. Theodorescu D, Sapinoso LM, Conaway MR et al (2004) Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10:3800–3806

    PubMed  CAS  Google Scholar 

  183. Titus B, Frierson HF Jr, Conaway M et al (2005) Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 65:7320–7327

    PubMed  CAS  Google Scholar 

  184. Tovar C, Rosinski J, Filipovic Z et al (2006) From the cover: small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. PNAS 103:1888–1893

    PubMed  CAS  Google Scholar 

  185. Trudel S, Stewart AK, Rom E et al (2006) The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107:4039–4046

    PubMed  CAS  Google Scholar 

  186. Tut VM, Braithwaite KL, Angus B et al (2001) Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer 84:270–275

    PubMed  CAS  Google Scholar 

  187. Uchida T, Wada C, Ishida H et al (1995) Infrequent involvement of mutations on neurofibromatosis type 1, H-Ras, K-Ras and N-Ras in urothelial tumors. Urol Int 55:63–67

    Article  PubMed  CAS  Google Scholar 

  188. Urakami S, Shiina H, Enokida H et al (2006) Epigenetic inactivation of wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical wnt/{beta}—catenin signaling pathway. Clin Cancer Res 12:383–391

    PubMed  CAS  Google Scholar 

  189. van Rhijn BW, Lurkin I, Radvanyi F et al (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61:1265–1268

    PubMed  Google Scholar 

  190. van Rhijn BW, van der Kwast TH, Vis AN et al (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64:1911–1914

    PubMed  Google Scholar 

  191. van Rhijn BW, Vis AN, van der Kwast TH et al (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21:1912–1921

    PubMed  Google Scholar 

  192. Vieillefond A, Beuzeboc P, Mignot L et al (2005) HER2 status in urothelial bladder cancer (UC): screening of patients eligible for a phase II randomized study of gemcitabine plus platinum salt with or without trastuzumab. In: Proceeding of the American Society of clinical oncology, vol 23

  193. Wang S, El-Deiry WS (2004) The p53 pathway: targets for the development of novel cancer therapeutics. Cancer Treat Res 119:175–187

    Article  PubMed  CAS  Google Scholar 

  194. Ward Y, Wang W, Woodhouse E et al (2001) Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol 21:5958–5969

    PubMed  CAS  Google Scholar 

  195. Wild PJ, Herr A, Wissmann C et al (2005) Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 11:4415–4429

    PubMed  CAS  Google Scholar 

  196. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

    PubMed  CAS  Google Scholar 

  197. Winquist E, Moore MJ, Chi KN et al (2005) A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 23:143–149

    PubMed  CAS  Google Scholar 

  198. Wolff EM, Liang G, Jones PA (2005) Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2:502–510

    PubMed  CAS  Google Scholar 

  199. Wu TT, Chen JH, Lee YH et al (2000) The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 163:758–760

    PubMed  CAS  Google Scholar 

  200. Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways [Review] [145 refs]. Nat Rev Cancer 5:713–725

    PubMed  CAS  Google Scholar 

  201. Wulfing C, Machiels J, Richel M et al (2006) A single arm, multicenter, open label, phase II study of lapatinib as second-line treatment of patients with advanced/metastatic transitional cell carcinoma of the urothelial tract [Abstract 4594]. J Clin Oncol 2006 ASCO Annual Meeting Proceedings, Part 1, vol 24

  202. Wulfing C, Eltze E, Yamini J et al (2005) Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival. Eur Urol 47:593–600

    PubMed  Google Scholar 

  203. Xia G, Kumar SR, Stein JP et al (2006) EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 25:769–780

    PubMed  CAS  Google Scholar 

  204. Yurakh AO, Ramos D, Calabuig-Farinas S et al (2006) Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 50:506–515

    PubMed  CAS  Google Scholar 

  205. Zieger K, Dyrskjot L, Wiuf C et al (2005) Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 11:7709–7719

    PubMed  CAS  Google Scholar 

  206. Zlotta AR, Noel JC, Fayt I et al (1999) Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette–Guerin intravesical therapy. J Urol 161:792–798

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, UVA HSC, P.O. Box 800716, Charlottesville, VA, 22908, USA

    Christopher Y. Thomas

  2. Department of Urology, UVA HSC, P.O. Box 800422, Charlottesville, VA, 22908, USA

    Dan Theodorescu

Authors
  1. Christopher Y. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan Theodorescu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dan Theodorescu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, C.Y., Theodorescu, D. Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World J Urol 24, 565–578 (2006). https://doi.org/10.1007/s00345-006-0119-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-006-0119-6

Keywords

Search

Navigation